rethinkPeptides Search
Menu
Home / Research library
Study breakdown

Thymosin Alpha-1 Plus Interferon for Chronic Hepatitis C: A Clinical Trial

RPEP-003811996Rasi, G; DiVirgilio, D; Mutchnick, M G; Colella, F; Sinibaldi-Vallebona, P; Pierimarchi, P; Valli, B; Garaci, E
RCTModerate evidence
The takeaway

Combination thymosin alpha-1 and lymphoblastoid interferon for chronic hepatitis C showed potential for improved treatment response over single-drug therapy.

1-year combination trial

Thymosin alpha-1 at 1 mg twice weekly combined with interferon for a full year in chronic hepatitis C patients

What the researchers found

Combination thymosin alpha-1 (1 mg twice weekly) and lymphoblastoid interferon was tested as a strategy to improve sustained response rates in chronic hepatitis C over interferon monotherapy.

Why it matters

Before direct-acting antivirals, hepatitis C treatment had very low cure rates. Thymosin alpha-1 combination therapy represented an attempt to boost immune-mediated viral clearance.

How the study worked

Randomized clinical trial assessing one year of combination thymosin alpha-1 and lymphoblastoid interferon treatment in patients with chronic hepatitis C.

What this study cannot tell us

Abstract doesn't detail response rates, sample size, or comparative arm design. Pre-direct-acting-antiviral era study may have limited current clinical relevance for HCV specifically.

How to read the evidence

Moderate evidence from an RCT. Systematic clinical trial design, but outcome details not available in abstract excerpt.

When this study was published

Published in 1996, before direct-acting antivirals transformed hepatitis C treatment. Thymosin alpha-1's immune-boosting role remains relevant in other contexts.

The bigger picture

While direct-acting antivirals have since revolutionized hepatitis C treatment, thymosin alpha-1 combination studies demonstrated the peptide's potential as an immune adjuvant in antiviral therapy.

Questions still open

  • Does thymosin alpha-1 combination therapy improve sustained viral response compared to interferon alone?
  • Could thymosin alpha-1's immune-boosting properties benefit modern HCV or other antiviral treatments?

Common questions

What is thymosin alpha-1?
Thymosin alpha-1 is a naturally occurring peptide from the thymus gland that enhances immune function, particularly T-cell activity. It's been approved in some countries as an immune modulator for viral hepatitis and as an adjunct to cancer immunotherapy.
Why combine thymosin alpha-1 with interferon?
Interferon alone had very low cure rates for hepatitis C (around 10-20% sustained response). Adding thymosin alpha-1 aimed to boost the immune system's ability to clear the virus, potentially improving cure rates through dual immune activation.

Read the original research

Combination thymosin alpha 1 and lymphoblastoid interferon treatment in chronic hepatitis C.

Gut, 39(5), 679-83

View on PubMed ↗

Citation

Rasi, G; DiVirgilio, D; Mutchnick, M G; Colella, F; Sinibaldi-Vallebona, P; Pierimarchi, P; Valli, B; Garaci, E. (1996). Combination thymosin alpha 1 and lymphoblastoid interferon treatment in chronic hepatitis C.. Gut, 39(5), 679-83.